The Deal
Sunday, November 22, 
1:35 am

GSK in $2.7B deal for sleeping drug

  Share     E-Mail    Discussion    Print Story
GlaxoSmithKline plc agreed Monday to pay Actelion Ltd. as much as Sfr2.735 billion ($2.74 billion) including milestone fees for the rights to develop and market the Swiss biotechnology firm's experimental sleep disorder drug almorexant.

Continue reading below

Also on Dealscape

The price tag includes an up-front payment of Sfr150 million, as well as milestone payments of up to Sfr415 million if the drug is successfully developed to treat primary insomnia. Actelion will be eligible for additional milestone payments depending on the successful development of two other major indications for the drug currently undergoing clinical trials.

Terms of the deal call for Actelion to keep developing the drug for use in insomnia, with Glaxo footing 40% of those costs. Concerning other indications, the companies said they will share all costs and profits resulting from their collaboration.

Actelion shares were up 2.7% at Sfr54 in late Monday morning trading in Zurich, giving the company a market value of Sfr6.6 billion. Shares rose as much as 9.1% to Sfr57.4, posting their biggest gain in nearly a year. In London, Glaxo shares were little changed at 1,202 pence ($23.95). - Renee Cordes

See full story on TheDeal.com




Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.